AGS 500
Alternative Names: AGS-500Latest Information Update: 01 Jul 2022
At a glance
- Originator Ben Gurion University
- Developer Neuromagen Pharma
- Class Antihyperglycaemics; Skin disorder therapies; Small molecules
- Mechanism of Action Telomerase activators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Hair disorders; Skin disorders; Type 1 diabetes mellitus
Most Recent Events
- 23 Jun 2022 Preclinical trials in Hair disorders in Israel (unspecified route), prior to June 2022 (Neuromagen Pharma pipeline, June 2022)
- 23 Jun 2022 Preclinical trials in Skin disorders in Israel (unspecified route), prior to June 2022 (Neuromagen Pharma pipeline, June 2022)
- 23 Jun 2022 Preclinical trials in Type 1 diabetes mellitus in Israel (unspecified route), prior to June 2022 (Neuromagen Pharma pipeline, June 2022)